Top 5 Health Care Stocks That Are Preparing To Pump In November
Portfolio Pulse from Lisa Levin
The article lists the top 5 oversold health care stocks, which are considered undervalued and present a buying opportunity. The stocks are Better Therapeutics Inc (BTTX), Heart Test Laboratories Inc (HSCS), SINTX Technologies Inc (SINT), Evelo Biosciences Inc (EVLO), and Arcutis Biotherapeutics Inc (ARQT). All these stocks have an RSI value below 30, indicating they are oversold.
November 03, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcutis Biotherapeutics announced the pricing of a $100 million public offering. Its stock fell 1.8% to close at $2.22 on Thursday.
The public offering could potentially increase the company's capital. However, the stock price has been falling, indicating a negative market sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Better Therapeutics recently launched AspyreRxTM for Type 2 diabetes. Its stock fell 6.1% to close at $0.15 on Thursday.
The launch of a new product could potentially increase the company's revenues. However, the stock price has been falling, indicating a negative market sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Evelo Biosciences reported that the primary endpoint in its Phase 2 clinical study was not achieved. Its stock fell 19.4% to close at $0.31 on Thursday.
The failure to achieve the primary endpoint in its clinical study could negatively impact the company's future revenues. The stock price has been falling, indicating a negative market sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Heart Test Laboratories entered into an equity distribution agreement with Maxim Group. Its stock fell 8.2% to close at $0.21 on Thursday.
The equity distribution agreement could potentially increase the company's capital. However, the stock price has been falling, indicating a negative market sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
SINTX Technologies was awarded a Phase II NIH grant for silicon nitride-PEEK 3D printed composite spinal implants. Its stock fell 6.9% to close at $0.42 on Thursday.
The grant could potentially increase the company's revenues. However, the stock price has been falling, indicating a negative market sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100